An observational study in Aging, Cognition Improvement and Cognition Disorders, sponsored by Westlake University. Recruiting at 2 sites in China. Open to participants aged 55 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Westlake University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Cognition Disorders with a site in China — 11 open to participants now, 11 under way, none of them phase 3. Cognition Disorders · China.
Among the 23 studies in Cognition Disorders with a site in China, this one is one of 5 that started in 2026, is one of 8 observational ones, reaches primary completion later than 10 of the 10 other live ones, and was the 20th registered.
399 studies on the registry are indexed under Cognition Disorders; 72 are open to participants now.
Browse Cognition Disorders studies →11 of the 23 studies in Cognition Disorders with a site in China are open now. Recruiting first, the newest first:
Yuju Wu · Sites in China
Ages 60–79 · Healthy volunteers
University of Electronic Science and Technology of China · Sites in China
Ages 18–55
Zhejiang University · Sites in China
Ages 60–80 · Healthy volunteers
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 60–85 · Healthy volunteers
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 40–75
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 46 Cognition Disorders studies recruiting now, 20 (43%) set no upper age limit and 11 (24%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.
This study: 55 Years to 90 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,800 is above the median of 137 across 108 observational studies indexed under Cognition Disorders.
Median enrollment 94 across the 15 interventional studies, 221 across the 8 observational. Of the 6 that completed or were terminated, 1 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 23 has an industry lead sponsor. The 10 most frequent:
Westlake University is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Westlake University has 1 study filed under Cognition Disorders — fewer than ten, so there is no comparison to draw.
3 of the studies in Cognition Disorders with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07573475Ke Dong, MDThe Effect of tDCS Combined With TMS on Cognitive Impairment and Motor Function After Stroke | 2027-05-01 |
| NCT07573501Ke Dong, MDDual-site Cross-frequency Coupled Transcranial Electrical Stimulation Modulates Working Memory of Patients With Post-stroke Cognitive Impairment | 2027-05-01 |
| NCT06904092Shanghai Mental Health CenterEfficacy and Mechanisms of TUS on Cognitive Deficits in Schizophrenia: Based on the Hippocampal-Prefrontal Circuit | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Cognition Disorders with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Westlake Ageing Cohort (WeAC) is a longitudinal cohort study conducted in Hangzhou, Zhejiang Province, China. The investigators aim to enroll 2,800 participants aged 55 years and older for long-term follow-up. The population will include individuals with neurodegenerative diseases or those at the prodromal stage of cognitive impairment, as well as healthy middle-aged and older adults serving as controls. The investigators will collect their sociodemographic, dietary, lifestyle, clinical, and neuroimaging data, as well as biological samples.
The investigators will recruit middle-aged and aged participants, including healthy controls and individuals with neurodegenerative disorders such as mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), etc. The aim of this study is to construct a longitudinal database that includes sociodemographic, lifestyle, clinical, neuroimaging, and multi-omics data. This database will be used to characterize the molecular signatures of neurodegenerative disorders. In addition, the investigators will identify biomarkers associated with neurodegenerative diseases. Furthermore, the investigators aim to uncover the mechanisms underlying the progression of mild cognitive impairment (MCI) and other neurodegenerative disorders.
All participants must be Chinese residents, regardless of their ethnicity.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cognitive function
Cognitive function will be evaluated using the Mini-Mental State Examination (MMSE, score range: 0-30, with higher scores indicating better cognitive function) and clinical diagnosis provided by physicians.
Time frame: 48 months
Gut microbiome
The gut microbiome will be profiled by metagenomic sequencing or ITS rRNA sequencing. In addition, fecal microbiota will be cultured, isolated, and identified.
Time frame: 48 months
Brain magnetic resonance imaging
Use brain magnetic resonance imaging (MRI) to measure the brain structure and function of participants.
Time frame: 48 months
Positron emission tomography
Assess the brain function and neurological disorders by positron emission tomography (PET).
Time frame: 48 months
Brain images relevant inspections
Other brain image relevant inspections required for study to measure brain structure and function of participants.
Time frame: 48 months
Electroencephalogram
Electroencephalogram (EEG) monitors the electrical activity of the brain. And further measure based on coupled EEG/MEG and eye-tracking.
Time frame: 48 months
Blood biochemical parameters
Blood biochemical parameters, including glucose and lipids, will be analyzed using an automated biochemical analyzer.
Time frame: 48 months
Serum inflammatory factors
Detect and assess serum inflammatory factors such as IL-1β, IL-6, and IL-12, in serum from participants.
Time frame: 48 months
Health and behavior monitoring
Use fitness trackers to record the physiological and behavioral data of participants.
Time frame: 48 months
Sleep data measurement
Use the polysomnography (PSG) to record the sleep data of participants to evaluate the sleep quality.
Time frame: 48 months
Continuous glucose monitoring
Use the continuous glucose monitoring (CGM) for dynamic blood glucose recording to determine the glycemic control of participants.
Time frame: 48 months
Environmental measurement
Use the environmental monitoring device to measure various exposure factors in the participants' living environment.
Time frame: 48 months
Multi-omics data
Multi omics results of detecting biological samples such as plasma, peripheral blood mononuclear cells (PBMCs), urine, feces, saliva, etc.
Time frame: 48 months
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jun 2026 (actual). Primary completion is estimated for Dec 2030, 54 months after the start.
Of 43 non-industry observational studies under Cognition Disorders, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 89. This study's planned 54 months is above that.
Counting every sponsor, half of 44 studies reached it within 41 months; a quarter within 13 and three quarters within 89.
Start moved once since we started tracking on Sep 25, 2026: Jan 2026 → Jun 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Westlake University